Behind the Lab Behind the Lab Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Partnership canine oncology Partnership canine oncology The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Heidelberg Transforming Science Day 2025 - Save the Date Heidelberg Transforming Science Day 2025 - Save the Date The Heidelberg Transforming Science Day profiles what makes our innovation different including our ground-breaking research and our diverse pipeline.
The unseen lameness problem in horses The unseen lameness problem in horses Learn more about the signs, causes and preventive measures of lameness in horses.
LastMile increases access to veterinary care in Africa LastMile increases access to veterinary care in Africa Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Meet the Partnering Team Video 2023 Meet the Partnering Team Video 2023 Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
The GPP Forum The GPP Forum The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
We’re looking for SAP developers to join our Global IT Department We’re looking for SAP developers to join our Global IT Department Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Transforming Science Day Transforming Science Day How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
Matthias Muenks Matthias Muenks Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
Largest European development center for biotechnology Largest European development center for biotechnology Boehringer Ingelheim inaugurates largest European development center for biotechnology
Finding the right inhaler for you Finding the right inhaler for you Living with a chronic respiratory disease can make life complicated. This discussion guide can be used to help start a conversation with a healthcare professional about inhaler choice.
New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares New spesolimab data show significant improvement in GPP flares
Boehringer Olaf Scholz break ground for innovation center Boehringer Olaf Scholz break ground for innovation center Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Gerhard Kraus, Global Head of IT Infrastructure Gerhard Kraus, Global Head of IT Infrastructure Gerhard Kraus, Global Head of IT Infrastructure "Improving the health of humans and animals is our vision. What we do can make a huge impact"
GioTag Final Data GioTag Final Data Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
Jens Barthelmes Jens Barthelmes My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!